Design and in vitro haemolytic evaluation of cryptolepine hydrochloride-loaded gelatine nanoparticles as a novel approach for the treatment of malaria

AAPS PharmSciTech

Volumn 13, Issue 2, 2012, Pages 568-581

  Kuntworbe, Noble ^a   Al Kassas, Raida ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

cryptolepine hydrochloride; gelatine type (A); haemolysis; malaria; nanoparticles

Indexed keywords

CRYPTOLEPINE; GELATIN; GLUCOSE; MANNITOL; NANOPARTICLE; SUCROSE;

ARTICLE; CONTROLLED STUDY; CRYOPROTECTION; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG FORMULATION; DRUG RELEASE; DRUG STABILITY; FREEZE DRYING; HEMOLYSIS; IN VITRO STUDY; ISOELECTRIC POINT; MALARIA; PARTICLE SIZE; PH; PRIORITY JOURNAL; PROCESS OPTIMIZATION; REDUCTION; ZETA POTENTIAL;

ANIMALS; ANTIMALARIALS; CHEMISTRY, PHARMACEUTICAL; CROSS-LINKING REAGENTS; CRYOPROTECTIVE AGENTS; DELAYED-ACTION PREPARATIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG CARRIERS; DRUG STABILITY; FREEZE DRYING; GELATIN; GLUCOSE; GLUTARAL; HEMOLYSIS; HYDROGEN-ION CONCENTRATION; INDOLE ALKALOIDS; ISOELECTRIC POINT; KINETICS; MANNITOL; NANOPARTICLES; NANOTECHNOLOGY; PARTICLE SIZE; QUINOLINES; RATS; SOLUBILITY; SUCROSE; TECHNOLOGY, PHARMACEUTICAL; TEMPERATURE;

EID: 84862858250     PISSN: None     EISSN: 15309932     Source Type: Journal    
DOI: 10.1208/s12249-012-9775-6     Document Type: Article

References (58)

1. RW Snow CA Guerra AM Noor HY Myint SI Hay 2005 The global distribution of clinical episodes of Plasmodium falciparum malaria Nature 434 7030 214 7 15759000 10.1038/nature03342 1:CAS:528:DC%2BD2MXitV2hsr4%3D (Pubitemid 40388051)
2. DE Bierer DM Fort CD Mendez J Luo PA Imbach LG Dubenko, et al. 1998 Ethnobotanical-directed discovery of the antihyperglycemic properties of cryptolepine: its isolation from Cryptolepis sanguinolenta, synthesis, and in vitro and in vivo activities J Med Chem 41 6 894 901 9526563 10.1021/jm9704816 1:CAS:528:DyaK1cXhtF2kt7k%3D (Pubitemid 28146244)
3. THM Jonckers S van Miert K Cimanga C Bailly P Colson M-C De Pauw-Gillet, et al. 2002 Synthesis, cytotoxicity, and antiplasmodial and antitrypanosomal activity of new neocryptolepine derivatives J Med Chem 45 16 3497 508 12139461 10.1021/jm011102i 1:CAS:528:DC%2BD38XkvVygtbw%3D (Pubitemid 34824038)
4. OA Olajide AM Ajayi CW Wright 2009 Anti-inflammatory properties of cryptolepine Phytother Res 23 10 1421 5 19288476 10.1002/ptr.2794 1:CAS:528:DC%2BD1MXhtlygu7%2FK
5. O Onyeibor SL Croft HI Dodson M Feiz-Haddad H Kendrick NJ Millington, et al. 2005 Synthesis of some cryptolepine analogues, assessment of their antimalarial and cytotoxic activities, and consideration of their antimalarial mode of action J Med Chem 48 7 2701 9 15801861 10.1021/jm040893w 1:CAS:528:DC%2BD2MXhvVSisbo%3D (Pubitemid 40516460)
6. CW Wright J Addae-Kyereme AG Breen JE Brown MF Cox SL Croft, et al. 2001 Synthesis and evaluation of cryptolepine analogues for their potential as new antimalarial agents J Med Chem 44 19 3187 94 11543688 10.1021/jm010929+ 1:CAS:528:DC%2BD3MXlvFymsr8%3D (Pubitemid 32862349)
7. SY Ablordeppey P Fan AM Clark A Nimrod 1999 Probing the N-5 region of the indoloquinoline alkaloid, cryptolepine for anticryptococcal activity Bioorg Med Chem 7 2 343 9 10218827 10.1016/S0968-0896(98)00244-2 1:CAS:528: DyaK1MXit1equ7s%3D (Pubitemid 29117098)
8. SR Hawley PG Bray PM O'Neill BK Park SA Ward 1996 The role of drug accumulation in 4-aminoquinoline antimalarial potency: the influence of structural substitution and physicochemical properties Biochem Pharmacol 52 5 723 33 8765470 10.1016/0006-2952(96)00354-1 1:CAS:528:DyaK28XltFOrs7Y%3D (Pubitemid 26276488)
9. TJ Egan R Hunter CH Kaschula HM Marques A Misplon J Walden 1999 Structure-function relationships in aminoquinolines: effect of amino and chloro groups on quinoline-hematin complex formation, inhibition of β-hematin formation, and antiplasmodial activity J Med Chem 43 2 283 91 10.1021/jm990437l (Pubitemid 30078160)
10. C Ansah NJ Gooderham 2002 The popular herbal antimalarial, extract of Cryptolepis sanguinolenta, is potently cytotoxic Toxicol Sci 70 2 245 51 12441369 10.1093/toxsci/70.2.245 1:CAS:528:DC%2BD38XptFOqsrc%3D (Pubitemid 36013657)
11. S Gibbons F Fallah CW Wright 2003 Cryptolepine hydrochloride: a potent antimycobacterial alkaloid derived from Cryptolepis sanguinolenta Phytother Res 17 4 434 6 12722159 10.1002/ptr.1284 1:CAS:528:DC%2BD3sXktlShu7Y%3D (Pubitemid 36565360)
12. J Lavrado A Paulo J Gut PJ Rosenthal R Moreira 2008 Cryptolepine analogues containing basic aminoalkyl side-chains at C-11: synthesis, antiplasmodial activity, and cytotoxicity Bioorg Med Chem Lett 18 4 1378 81 18207399 10.1016/j.bmcl.2008.01.015 1:CAS:528:DC%2BD1cXitlais78%3D (Pubitemid 351226539)
13. S Seville RM Phillips SD Shnyder CW Wright 2007 Synthesis of cryptolepine analogues as potential bioreducible anticancer agents Bioorg Med Chem 15 19 6353 60 17643990 10.1016/j.bmc.2007.06.062 1:CAS:528:DC%2BD2sXovFOit7w%3D (Pubitemid 47212739)
14. M Singh MP Singh S Ablordeppey 1996 In vitro studies with liposomal cryptolepine Drug Dev Ind Pharm 22 4 377 81 10.3109/03639049609042003 1:CAS:528:DyaK28XhvFemtrc%3D (Pubitemid 26127995)
15. E Fuse T Kobayashi M Inaba Y Sugiyama 1995 Prediction of the maximal tolerated dose (MTD) and therapeutic effect of anticancer drugs in humans: integration of pharmacokinetics with pharmacodynamics and toxicodynamics Cancer Treat Rev 21 2 133 57 7758004 10.1016/0305-7372(95)90024-1 1:CAS:528: DyaK2MXmslGqt7c%3D
16. HL Wong R Bendayan AM Rauth Y Li XY Wu 2007 Chemotherapy with anticancer drugs encapsulated in solid lipid nanoparticles Adv Drug Deliv Rev 59 6 491 504 17532091 10.1016/j.addr.2007.04.008 1:CAS:528:DC%2BD2sXpt1CqtrY%3D (Pubitemid 47259227)
17. NS Santos-Magalhães VCF Mosqueira 2010 Nanotechnology applied to the treatment of malaria Adv Drug Deliv Rev 62 4-5 560 75 19914313 10.1016/j.addr.2009.11.024
18. Greenwood BM, Fidock DA, Kyle DE, Kappe SHI, Alonso PL, Collins FH, et al. Malaria: progress, perils, and prospects for eradication. Ann Arbor: American Society for Clinical Investigation; 2008.
19. SE Francis DJ Sullivan DE Goldberg 1997 Hemoglobin metabolism in the malaria parasite Plasmodium falciparum Annu Rev Microbiol 51 1 97 123 9343345 10.1146/annurev.micro.51.1.97 1:CAS:528:DyaK2sXms1Shsbw%3D (Pubitemid 27433044)
20. L Lim GI McFadden 2010 The evolution, metabolism and functions of the apicoplast Philos Trans R Soc B Biol Sci 365 1541 749 63 10.1098/rstb.2009.0273 1:CAS:528:DC%2BC3cXjtFCqtb8%3D
21. C Spry CLL Chai K Kirk KJ Saliba 2005 A class of pantothenic acid analogs inhibits Plasmodium falciparum pantothenate kinase and represses the proliferation of malaria parasites Antimicrob Agents Chemother 49 11 4649 57 16251308 10.1128/AAC.49.11.4649-4657.2005 1:CAS:528:DC%2BD2MXht1Siu73N (Pubitemid 41552596)
22. K Marsh D Forster C Waruiru I Mwangi M Winstanley V Marsh, et al. 1995 Indicators of life-threatening malaria in African children N Engl J Med 332 21 1399 404 7723795 10.1056/NEJM199505253322102 1:STN:280:DyaK2M3ktVKktQ%3D%3D
23. Andrej T, Matjaz Jereb, Igor Muzlovic, Prabhu RM. Clinical review: severe malaria. Critical Care [serial on the Internet]. 2003; 7. Available from: http://ccforum.com/content/7/4/315
24. G Peter AL Manuel A Shetty 2011 Study comparing the clinical profile of complicated cases of Plasmodium falciparum malaria among adults and children Asian Pac J Trop Dis 1 1 35 7 10.1016/S2222-1808(11)60008-X
25. MP Desai V Labhasetwar GL Amidon RJ Levy 1996 Gastrointestinal uptake of biodegradable microparticles: effect of particle size Pharm Res 13 12 1838 45 8987081 10.1023/A:1016085108889 1:CAS:528:DyaK2sXltVSquw%3D%3D (Pubitemid 27034116)
26. J Shaikh DD Ankola V Beniwal D Singh MNVR Kumar 2009 Nanoparticle encapsulation improves oral bioavailability of curcumin by at least 9-fold when compared to curcumin administered with piperine as absorption enhancer Eur J Pharm Sci 37 3-4 223 30 19491009 10.1016/j.ejps.2009.02.019 1:CAS:528: DC%2BD1MXms1Oksrg%3D
27. P Caliceti FM Veronese 2003 Pharmacokinetic and biodistribution properties of poly(ethylene glycol)-protein conjugates Adv Drug Deliv Rev 55 10 1261 77 14499706 10.1016/S0169-409X(03)00108-X 1:CAS:528:DC%2BD3sXnt1yqsb0%3D (Pubitemid 37464561)
28. C Losa L Marchal-Heussler F Orallo JLV Jato MJ Alonso 1993 Design of new formulations for topical ocular administration: polymeric nanocapsules containing metipranolol Pharm Res 10 1 80 7 8094245 10.1023/A:1018977130559 1:CAS:528:DyaK3sXoslGltg%3D%3D (Pubitemid 23020842)
29. E Cauchetier M Paul D Rivollet H Fessi A Astier M Deniau 2003 Therapeutic evaluation of free and nanocapsule-encapsulated atovaquone in the treatment of murine visceral leishmaniasis Ann Trop Med Parasitol 97 259 68 12803857 10.1179/000349803235001840 1:CAS:528:DC%2BD3sXltlGrurY%3D (Pubitemid 36606358)
30. V Troger JL Fischel P Formento J Gioanni G Milano 1992 Effects of prolonged exposure to cisplatin on cytotoxicity and intracellular drug concentration Eur J Cancer 28 1 82 6 1567698 10.1016/0959-8049(92)90391-E 1:CAS:528:DyaK38XktVSgu7o%3D
31. VCF Mosqueira PM Loiseau C Bories P Legrand J-P Devissaguet G Barratt 2004 Efficacy and pharmacokinetics of intravenous nanocapsule formulations of halofantrine in plasmodium Berghei-infected mice Antimicrob Agents Chemother 48 4 1222 8 15047523 10.1128/AAC.48.4.1222-1228.2004 1:CAS:528:DC%2BD2cXjtVKqsr4%3D (Pubitemid 38405476)
32. M Joshi S Pathak S Sharma V Patravale 2008 Design and in vivo pharmacodynamic evaluation of nanostructured lipid carriers for parenteral delivery of artemether: Nanoject Int J Pharm 364 1 119 26 18765274 10.1016/j.ijpharm.2008.07.032 1:CAS:528:DC%2BD1cXht1yktbrO
33. D Bhadra AK Yadav S Bhadra NK Jain 2005 Glycodendrimeric nanoparticulate carriers of primaquine phosphate for liver targeting Int J Pharm 295 1-2 221 33 15848007 10.1016/j.ijpharm.2005.01.026 1:CAS:528:DC%2BD2MXjtl2rsrs%3D (Pubitemid 40558805)
34. Owais M, Varshney CG, Choudhury A, Chandra S, et al. Chloroquine encapsulated in malaria-infected erythrocyte-specific antibody-bearing liposomes effectively controls chloroquine-resistant Plasmodium Berghei infections in mice. Washington, DC: American Society for Microbiology; 1995.
35. PAM Peeters K de Leest WMC Eling DJA Crommelin 1989 Chloroquine blood levels after administration of the liposome-encapsulated drug in relation to therapy of murine malaria Pharm Res 6 9 787 93 2682591 10.1023/A:1015927614920 1:CAS:528:DyaL1MXmtVWms7c%3D (Pubitemid 19247849)
36. TJ Egan DC Ross PA Adams 1994 Quinoline anti-malarial drugs inhibit spontaneous formation of [beta]-haematin (malaria pigment) FEBS Lett 352 1 54 7 7925942 10.1016/0014-5793(94)00921-X 1:CAS:528:DyaK2cXmslWgu78%3D (Pubitemid 24291758)
37. K Ofokansi G Winter G Fricker C Coester 2010 Matrix-loaded biodegradable gelatin nanoparticles as new approach to improve drug loading and delivery Eur J Pharm Biopharm 76 1 1 9 20420904 10.1016/j.ejpb.2010.04.008 1:CAS:528:DC%2BC3cXhtVekt7bM
38. CN Berger P Le Donne H Windemann 2005 Use of substances of animal origin in pharmaceutics and compliance with the TSE-risk guideline-a market survey Biologicals 33 1 1 7 15713551 10.1016/j.biologicals.2004.10.002 (Pubitemid 40248761)
39. S Peano G Reiner M Carbonatto L Bodenbender P Boland KJ Abel 2000 Determination of the clearance factor for transmissible spongiform encephalopathy agents during the manufacturing process of polygeline Intensive Care Med 26 5 608 12 10923737 10.1007/s001340051211 1:STN:280: DC%2BD3M%2Fjt1eqtA%3D%3D (Pubitemid 30325879)
40. AH Grobben PJ Steele RA Somerville DM Taylor BEC Schreuder 2005 Inactivation of the BSE agent by the heat and pressure process for manufacturing gelatine Vet Rec 157 10 277 81 16157568 1:STN:280:DC%2BD2MvoslOjtg%3D%3D (Pubitemid 41319438)
41. RC Oppenheim NF Stewart 1979 The manufacture and tumour cell uptake of nanoparticles labelled with fluorescein isothiocyanate Drug Dev Ind Pharm 5 6 563 71 10.3109/03639047909055680 1:CAS:528:DyaL3cXitVemsrk%3D
42. E Leo VM Angela R Cameroni F Forni 1997 Doxorubicin-loaded gelatin nanoparticles stabilized by glutaraldehyde: involvement of the drug in the cross-linking process Int J Pharm 155 1 75 82 10.1016/S0378-5173(97)00149-X 1:CAS:528:DyaK2sXlslWisL4%3D (Pubitemid 27368124)
43. M Nahar D Mishra V Dubey NK Jain 2008 Development, characterization, and toxicity evaluation of amphotericin B-loaded gelatin nanoparticles Nanomedicine: Nanotechnol Biol Med 4 3 252 61 10.1016/j.nano.2008.03.007 1:CAS:528: DC%2BC3cXmtVCmuw%3D%3D
44. C Coester J Kreuter H von Briesen K Langer 2000 Preparation of avidin-labelled gelatin nanoparticles as carriers for biotinylated peptide nucleic acid (PNA) Int J Pharm 196 2 147 9 10699706 10.1016/S0378-5173(99)00409- 3 1:CAS:528:DC%2BD3cXhtl2qtrY%3D (Pubitemid 30105731)
45. JC Zillies K Zwiorek F Hoffmann A Vollmar TJ Anchordoquy G Winter, et al. 2008 Formulation development of freeze-dried oligonucleotide-loaded gelatin nanoparticles Eur J Pharm Biopharm 70 2 514 21 18582569 10.1016/j.ejpb.2008.04. 026 1:CAS:528:DC%2BD1cXhtFOmtbbJ
46. CJ Coester K Langer H Von Briesen J Kreuter 2000 Gelatin nanoparticles by two step desolvation-a new preparation method, surface modifications and cell uptake J Microencapsul 17 2 187 93 10738694 10.1080/026520400288427 1:CAS:528:DC%2BD3cXjs1Ghu7k%3D (Pubitemid 30135796)
47. E Leo R Cameroni F Forni 1999 Dynamic dialysis for the drug release evaluation from doxorubicin-gelatin nanoparticle conjugates Int J Pharm 180 1 23 30 10089288 10.1016/S0378-5173(98)00401-3 1:CAS:528:DyaK1MXhvFCru7g%3D (Pubitemid 29131439)
48. International Conference on Harmonization. Guidance to industries: ICH topic Q1A(R2) stability testing for new drug substances and products. Brussels: International Conference on Harmonization; 2003.
49. Kuntworbe N, Martini N, Brimble M, Alani GR, Al-Kassas R. Detection and quantification of the antimalarial compound cryptolepine by HPLC. Portland: Oregon Convention Centre; 2010 [cited Abstract number 699 04/08/2010]. Available from: https://www.controlledreleasesociety.org/customer/source/Meetings/ PresentationFiles/4927-1.pdf.
50. D Salauze D Decouvelaere 1994 In vitro assessment of the haemolytic potential of candidate drugs Comp Haematol Int 4 1 34 6 10.1007/BF00368264 1:CAS:528:DyaK2MXislOlu7w%3D (Pubitemid 24171309)
51. G Dalwadi B Sunderland 2009 An ion pairing approach to increase the loading of hydrophilic and lipophilic drugs into PEGylated PLGA nanoparticles Eur J Pharm Biopharm 71 2 231 42 18768159 10.1016/j.ejpb.2008.08.004 1:CAS:528:DC%2BD1MXitVShsLY%3D
52. S Salmaso N Elvassore A Bertucco P Caliceti 2009 Production of solid lipid submicron particles for protein delivery using a novel supercritical gas-assisted melting atomization process J Pharm Sci 98 2 640 50 18484622 10.1002/jps.21434 1:CAS:528:DC%2BD1MXhs1Kmt7Y%3D
53. SW Larsen AB Frost J Ostergaard H Marcher C Larsen 2008 On the mechanism of drug release from oil suspensions in vitro using local anesthetics as model drug compounds Eur J Pharm Sci 34 1 37 44 18374550 10.1016/j.ejps.2008.02.005 1:CAS:528:DC%2BD1cXlslyktr8%3D
54. S D'Souza P DeLuca 2005 Development of a dialysis in vitro release method for biodegradable microspheres AAPS PharmSciTech 6 2 E323 8 16353991 10.1208/pt060242 (Pubitemid 41631740)
55. S Goutelle M Maurin F Rougier X Barbaut L Bourguignon M Ducher, et al. 2008 The Hill equation: a review of its capabilities in pharmacological modelling Fundam Clin Pharmacol 22 6 633 48 19049668 10.1111/j.1472-8206.2008. 00633.x 1:CAS:528:DC%2BD1MXhvV2msQ%3D%3D
56. S Young M Wong Y Tabata AG Mikos 2005 Gelatin as a delivery vehicle for the controlled release of bioactive molecules J Control Release 109 1-3 256 74 16266768 10.1016/j.jconrel.2005.09.023 1:CAS:528:DC%2BD2MXht12jt7nF (Pubitemid 41737269)
57. Y Tabata Y Ikada 1998 Protein release from gelatin matrices Adv Drug Deliv Rev 31 3 287 301 10837630 10.1016/S0169-409X(97)00125-7 1:CAS:528:DyaK1cXhvVSjsb4%3D (Pubitemid 28191870)
58. TK Bock BW Müller 1994 A novel assay to determine the hemolytic activity of drugs incorporated in colloidal carrier systems Pharm Res 11 4 589 91 8058621 10.1023/A:1018987120738 1:CAS:528:DyaK2cXivVSisLw%3D (Pubitemid 24144456)